The below average efficacy of last year’s influenza vaccine (which was only 20 to 30 percent effective) can be attributed to a mutation in the H3N2 strain, a new study reports. With the mutation, most people receiving the egg-grown vaccine did not have immunity against H3N2 viruses that circulated last year.